These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7586933)

  • 1. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
    Transon C; Leemann T; Vogt N; Dayer P
    Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
    Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
    Appel S; Rüfenacht T; Kalafsky G; Tetzloff W; Kallay Z; Hitzenberger G; Kutz K
    Am J Cardiol; 1995 Jul; 76(2):29A-32A. PubMed ID: 7604792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
    Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
    J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
    Tang C; Shou M; Rodrigues AD
    Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.
    Andersson TB; Bredberg E; Ericsson H; Sjöberg H
    Drug Metab Dispos; 2004 Jul; 32(7):715-21. PubMed ID: 15205386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
    Meadowcroft AM; Williamson KM; Patterson JH; Hinderliter AL; Pieper JA
    J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
    Asberg A; Holdaas H
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
    Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
    Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver.
    Leemann T; Transon C; Dayer P
    Life Sci; 1993; 52(1):29-34. PubMed ID: 8417277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interactions: how scared should we be?
    Shapiro LE; Shear NH
    CMAJ; 1999 Nov; 161(10):1266-7. PubMed ID: 10584089
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
    Mc Donnell CG; Shorten G; Van Pelt FN
    Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.